Search research articles
Contact Us
Filters
Showing results (1-10 of 343) with videos related to
Page
of 35
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
March 15, 2022
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer
Michel Ducreux
Clinical and Experimental Gastroenterology
|
June 23, 2011
Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
Michel Ducreux
Soins; La Revue De Reference Infirmiere
|
December 23, 2019
[Oral treatments for cancer]
Michel Ducreux
The Lancet. Oncology
|
February 28, 2017
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?
Michel Ducreux
Gastroenterologie Clinique Et Biologique
|
March 28, 2006
[Clinical cases: a well-differentiated endocrine tumor]
Michel Ducreux, Eric Baudin
The Lancet. Oncology
|
November 5, 2020
Results from the PROPHYLOCHIP-PRODIGE 15 trial - Authors' reply
Diane Goéré, Michel Ducreux
Case Reports in Oncology
|
July 27, 2023
Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
Paul Matte, Michel Ducreux
La Revue Du Praticien
|
April 17, 2004
[Colorectal cancer: contribution of new diagnostic tools]
Clarisse Dromain, Michel Ducreux
La Revue Du Praticien
|
April 3, 2002
[Biotherapy of neuroendocrine tumors]
Philippe Chanson, Michel Ducreux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors
Julien Hadoux, Michel Ducreux
Page
of 35
Search research articles
Search
Showing results (1-10 of 343) with videos related to
Sort By:
Page
of 35
Clinical Advances in Hematology & Oncology : H&O
|
March 15, 2022
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer
Michel Ducreux
Clinical and Experimental Gastroenterology
|
June 23, 2011
Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
Michel Ducreux
Soins; La Revue De Reference Infirmiere
|
December 23, 2019
[Oral treatments for cancer]
Michel Ducreux
The Lancet. Oncology
|
February 28, 2017
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?
Michel Ducreux
Gastroenterologie Clinique Et Biologique
|
March 28, 2006
[Clinical cases: a well-differentiated endocrine tumor]
Michel Ducreux, Eric Baudin
The Lancet. Oncology
|
November 5, 2020
Results from the PROPHYLOCHIP-PRODIGE 15 trial - Authors' reply
Diane Goéré, Michel Ducreux
Case Reports in Oncology
|
July 27, 2023
Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
Paul Matte, Michel Ducreux
La Revue Du Praticien
|
April 17, 2004
[Colorectal cancer: contribution of new diagnostic tools]
Clarisse Dromain, Michel Ducreux
La Revue Du Praticien
|
April 3, 2002
[Biotherapy of neuroendocrine tumors]
Philippe Chanson, Michel Ducreux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors
Julien Hadoux, Michel Ducreux
Page
of 35